These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28032455)

  • 1. In silico design and bioevaluation of selective benzotriazepine BRD4 inhibitors with potent antiosteoclastogenic activity.
    Deepak V; Wang B; Koot D; Kasonga A; Stander XX; Coetzee M; Stander A
    Chem Biol Drug Des; 2017 Jul; 90(1):97-111. PubMed ID: 28032455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
    Raj U; Kumar H; Varadwaj PK
    J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1).
    Hügle M; Lucas X; Weitzel G; Ostrovskyi D; Breit B; Gerhardt S; Einsle O; Günther S; Wohlwend D
    J Med Chem; 2016 Feb; 59(4):1518-30. PubMed ID: 26731611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design.
    Duffy BC; Liu S; Martin GS; Wang R; Hsia MM; Zhao H; Guo C; Ellis M; Quinn JF; Kharenko OA; Norek K; Gesner EM; Young PR; McLure KG; Wagner GS; Lakshminarasimhan D; White A; Suto RK; Hansen HC; Kitchen DB
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2818-23. PubMed ID: 26022843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico study directed towards identification of novel high-affinity inhibitors targeting an oncogenic protein: BRD4-BD1.
    Tumdam R; Kumar A; Subbarao N; Balaji BS
    SAR QSAR Environ Res; 2018 Dec; 29(12):975-996. PubMed ID: 30411639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.
    Rodríguez Y; Gerona-Navarro G; Osman R; Zhou MM
    Proteins; 2020 Mar; 88(3):414-430. PubMed ID: 31587361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors.
    Borysko P; Moroz YS; Vasylchenko OV; Hurmach VV; Starodubtseva A; Stefanishena N; Nesteruk K; Zozulya S; Kondratov IS; Grygorenko OO
    Bioorg Med Chem; 2018 Jul; 26(12):3399-3405. PubMed ID: 29764756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of a crystalline water network in docking-based virtual screening: a case study of BRD4.
    Zhong H; Wang Z; Wang X; Liu H; Li D; Liu H; Yao X; Hou T
    Phys Chem Chem Phys; 2019 Dec; 21(45):25276-25289. PubMed ID: 31701109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins.
    Raux B; Voitovich Y; Derviaux C; Lugari A; Rebuffet E; Milhas S; Priet S; Roux T; Trinquet E; Guillemot JC; Knapp S; Brunel JM; Fedorov AY; Collette Y; Roche P; Betzi S; Combes S; Morelli X
    J Med Chem; 2016 Feb; 59(4):1634-41. PubMed ID: 26735842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of benzo[cd]indol-2(1H)-ones derivatives as BRD4 inhibitors.
    Feng Y; Xiao S; Chen Y; Jiang H; Liu N; Luo C; Chen S; Chen H
    Eur J Med Chem; 2018 May; 152():264-273. PubMed ID: 29730189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.
    Hounoki H; Sugiyama E; Mohamed SG; Shinoda K; Taki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Miyahara T
    Bone; 2008 Apr; 42(4):765-74. PubMed ID: 18242157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationship studies of N6-benzoyladenine derivatives as novel BRD4 inhibitors.
    Noguchi-Yachide T; Sakai T; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem; 2015 Mar; 23(5):953-9. PubMed ID: 25678016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway.
    Rantlha M; Sagar T; Kruger MC; Coetzee M; Deepak V
    Arch Pharm Res; 2017 Jan; 40(1):79-87. PubMed ID: 27384064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.
    Hewings DS; Fedorov O; Filippakopoulos P; Martin S; Picaud S; Tumber A; Wells C; Olcina MM; Freeman K; Gill A; Ritchie AJ; Sheppard DW; Russell AJ; Hammond EM; Knapp S; Brennan PE; Conway SJ
    J Med Chem; 2013 Apr; 56(8):3217-27. PubMed ID: 23517011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.